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Abstract
Background—Despite a concerted effort from many laboratories, the critical subunits that
participate in vascular smooth muscle cell (VSMC) NADPH oxidase function have yet to be
elucidated. Given the potential therapeutic importance of cell-specific inhibition of NADPH oxidase,
we investigated the role of Nox activator 1 (NoxA1), a homologue of p67phox, in VSMC NADPH
oxidase function, and atherosclerosis.
Methods and Results—The presence of NoxA1 in mouse aortic VSMC was confirmed by RT-
PCR and sequencing. NoxA1/p47phox interaction, following thrombin treatment, was observed by
immunoprecipitation/Western analysis of lysates from p47phox−/− VSMC transfected with
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After decades of investigation, there remains a need for preventive strategies that can reduce atherosclerosis and atherothrombosis, which
represent the most common cause of death and disability in the United States. Despite many important advances in the treatment of
cardiovascular diseases, elucidation of specific therapies that target vascular wall cells has been elusive. An important limitation of
targeting intracellular signaling pathways in dysfunctional vascular cells is that most of them are present ubiquitously and are necessary
for normal cellular function. Many investigators have studied the hypothesis that regulated production of reactive oxygen species (ROS)
and oxidative stress in vascular cells is important in atherogenesis and that it may be possible to specifically inhibit upregulation of ROS
production in vascular cells and in so limit atherogenesis and atherothrombosis. However, the pathways that produce ROS – NADPH
oxidase, xanthine oxidase, cyclooxygenase, lipogenase and others – are all necessary for normal cellular function. The experiments
described here were designed to test the strategy of targeting a specific component of NADPH oxidase, arguably the most important
regulated system for ROS production in vascular cells. To do so, we examined modulation of NoxA1, a NADPH oxidase component
necessary for upregulation of superoxide production in vascular smooth muscle cells. Our studies indicate that NoxA1 is critically
important in the NADPH oxidase-mediated overexpression of ROS, characteristic of vascular diseases. Although specific inhibitors of
NoxA1 are not known, this work suggests that the strategy of cell specific modulation of NADPH oxidase function is a therapeutic
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adenoviral HA-NoxA1 and Myc-p47phox. Infection with AdNoxA1 significantly enhanced
thrombin-induced ROS generation in wild-type but not in p47phox−/− and Nox1−/− VSMC.
Thrombin-induced ROS production and VSMC proliferation were significantly reduced following
downregulation of NoxA1 using shRNA. Infection with NoxA1 shRNA but not scrambled shRNA
significantly decreased thrombin-induced activation of redox-sensitive protein kinases―Janus
kinase 2, Akt and p38 mitogen-activated protein kinase―in VSMC. Adenovirus-mediated
overexpression of NoxA1 in guidewire-injured mouse carotid arteries significantly increased
superoxide production in medial VSMC and enhanced neointimal hyperplasia. NoxA1 expression
was significantly increased in aortas and atherosclerotic lesions of ApoE−/− mice compared with their
age-matched wild-type mice. Further, in contrast to p67phox, immunoreactive NoxA1 is present in
intimal and medial SMC of human early carotid atherosclerotic lesions.
Conclusions—NoxA1 is the functional homologue of p67phox in VSMC and regulates redox
signaling and VSMC phenotype. These findings support the potential for modulation of NoxA1
expression as a viable approach for the treatment of vascular diseases.
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INTRODUCTION
NADPH oxidases are the most important of the superoxide (O2.−) producing enzymes for
vascular pathologies such as hypertension and atherosclerosis.1 Vessel wall NADPH oxidases
are similar to the well-characterized neutrophil enzyme active in host defense but vary
kinetically and in subunit composition, with differences reported among cell types and vascular
beds.2
Given the large number of potential combinations of subunits, NADPH oxidases are
categorized based upon the catalytic subunit, the Nox protein, and which of the five homologues
of Nox is present in a particular complex. At least four Nox homologues are present in one or
another vessel wall cell type. Rodent aortic vascular smooth muscle cells (VSMC) contain
Nox1 and Nox4,3,4 which directly interact with p22phox, a subunit common to all vascular
oxidases,5 to form a functional NADPH oxidase. Nox1 is inactive under basal conditions,6
whereas Nox4 is constitutively active.7,8 Nox2 is expressed at very low levels in rodent
VSMC4 and targeted deletion of NOX2 gene had no effect on agonist-induced O2.− generation
in these cells.9 Very recently, it has been reported that four isoforms of Nox5 are expressed in
human aortic smooth muscle cells and Nox5 shRNA significantly inhibited platelet-derived
growth factor stimulated ROS production and cell proliferation.10
The Nox1-based NADPH oxidase contains regulatory cytosolic components p47phox, NoxA1
and Rac1, in addition to Nox1 and p22phox which form the membrane bound cytochrome
b558. Both p22phox and p47phox have been shown to be essential for NADPH oxidase activity
in VSMC. Transfection of VSMC with anitsense p22phox cDNA significantly inhibits agonist-
stimulated NADH/NADPH-dependent O2.− production.11 We and others have previously
demonstrated that genetic deletion of p47phox inhibits agonist-induced O2.− production in
VSMC.9,12,13 Both p22phox and p47phox are widely expressed in nonvascular cells. For this
reason, a strategy of targeting either p22phox or p47phox is a non-selective means to inhibiting
vascular wall NADPH oxidase activity. The Nox2-based NADPH oxidase also contains
p47phox and Rac1 in addition to Nox2. In this complex, p67phox is a necessary subunit for
activation.14
Whether p67phox is a necessary component of the VSMC NADPH oxidase, and if not what
subunit substitutes for p67phox, remains controversial. We reported that p67phox was not
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expressed in rat aortic VSMC.15 However, p67phox mRNA was reported in VSMC from
human resistance arteries.16 The report of novel human and mouse homologues of p47phox
(NoxO1, Nox organizer 1) and p67phox (NoxA1, Nox activator 1) raised the question of the
subunit composition of NADPH oxidases in vascular cells.17,18 The question of the role of
p47phox and p67phox versus NoxO1 and NoxA1 is complicated by reports of their
interdependence in some systems. Expression of Nox1 with NoxO1 and NoxA1 produced
stimulus-independent generation of O2.− in HEK293 cells and the constitutive activation of
Nox1 was lost when NoxO1 was replaced with p47phox.18 This is because NoxO1 lacks the
autoinhibitory region present in p47phox and therefore can localize to cell membrane under
basal conditions.19 However, this interdependence may not exist in VSMC. NoxA1 is
expressed in the cytoplasm of VSMC and treatment of cells with epidermal growth factor
induces the translocation of NoxA1 and p47phox to the cell membrane.20 In addition, antisense
inhibition of NoxA1 attenuates agonist-induced O2.− production in mouse VSMC. Rac1 is
directly involved in the activation of Nox1, perhaps via its interaction with NoxA1.21,22
The present study was designed to determine whether NoxA1 was an important functional
component of the VSMC NADPH oxidase and, if so, whether it might represent an appropriate
target for therapeutic intervention. We examined the expression of NoxA1 and its interaction
with p47phox in mouse aortic VSMC. Suppression of NoxA1 expression decreased whereas
overexpression increased thrombin-induced O2.− production. Localized overexpression of
NoxA1 significantly enhanced neointimal hyperplasia in injured mouse carotid arteries.
NoxA1 expression is increased in aortas and atherosclerotic lesions from ApoE−/− mice.
Further, NoxA1 expression is correlated with the progression of atherosclerotic lesions whereas
both NoxA1 and p67phox were present in advanced atherosclerotic lesions of human carotid
arteries. These data suggest that it may be possible to reduce vascular lesion formation and its
complications by targeting NoxA1 with specific therapeutic interventions.
Materials and Methods
Cell Culture
Mouse aortic VSMC were isolated from 4-month old male C57BL/6J mice as previously
described23 (see supplemental materials).
Reverse transcriptase-Polymerase Chain Reaction (RT-PCR) and Sequencing of NoxA1
The first-strand cDNA synthesis was carried out from total RNA isolated from mouse aortic
VSMC using SuperScript II reverse transcriptase (Invitrogen) as per manufacturer’s
instructions. PCR was performed with primers generated from the mouse NoxA1 sequence (5′-
TTCCAGCTGCAGAGGTTCCAG-3′ as forward primer and 5′-
AAGTCCAAATCCTCCGGTCT-3′ as reverse primer) to amplify a 923-bp fragment (247–
1169 bp) of the NoxA1 gene. RT-PCR to determine the expression of p67phox in mouse VSMC
was performed with primers generated from the mouse p67phox sequence (5′-
CTACCTGGAGCCAGTTGAGC-3′ as forward primer and 5′-
GGGCAGCCTCATAACTGAAG-3′ as reverse primer) to amplify a 636-bp fragment (876–
1411 bp) of the p67phox gene (see supplemental materials for details).
Retroviral Vector Construction and Infection of Mouse Aortic VSMC
A double-stranded hairpin oligonucleotide designed to target the mouse NoxA1 cDNA
nucleotides 376–394 (5′-TACAACATGGCATCAGCAC-3′) of NoxA1 gene was cloned into
the BglII/HindIII site of pSUPER.retro.puro vector to generate NoxA1 shRNA (see
supplemental materials for details).
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Adenovirus Construction and Infection of Mouse Aortic VSMC
Adenoviral constructs encoding HA-NoxA1 and Myc-p47phox and infection of VSMC were
performed as described in the supplemental materials.
Measurement of Intracellular Reactive Oxygen Species
Intracellular hydrogen peroxide levels in VSMC were measured using 2',7'-dichlorofluorescein
diacetate as described previously.24 Superoxide levels in mouse VSMC25 and in the aortas9
were measured by staining with dihydroethidium. Superoxide anion generation in thrombin-
treated mouse VSMC suspension was measured using chemiluminescence enhancer L012 [8-
amino-5-chloro-7-phenylpyridol[3,4-d]pyridazine-1,4(2H,3H)dione] (see supplemental
materials for details).
Immunoprecipitation and Western Blot Analysis
Immunoprecipitation and Western blotting were preformed as described26 (see supplemental
materials).
[3H]Thymidine Incorporation Assay
[3H] Thymidine incorporation into DNA of VSMC treated with or without thrombin were
performed as described26 (see supplemental materials).
VSMC Migration Assay
VSMC migration was determined in a scratch wound assay (see supplemental materials).
Real-time RT-PCR to Measure NoxA1 Expression
Detailed information regarding RNA extraction and real-time RT-PCR for NoxA1 expression
is available in the supplemental materials.
Mice and Diet
Wild-type and apoE−/− mice were purchased from Jackson Laboratory. Mice were maintained
at 22°C with 12-hour light/dark cycle and given free access to food and water. Mice on high-
fat diet were maintained on standard rodent chow until 4 weeks of age and then fed a Western-
type diet (Harlan Teklad / TD88137) for 12 weeks. All procedures involving the experimental
animals were performed in accordance with protocols approved by UNC IACUC according to
NIH guidelines.
Carotid Artery Injury and NoxA1 Overexpression
The right external and common carotid arteries were surgically exposed in 10-week old,
anesthetized wild-type mice. Angioplasty guide wire, introduced through an arteriotomy made
in external carotid artery, was used to denude the endothelium in the artery. The denuded artery
was flushed with PBS and a 1 cm segment isolated with ligatures and a 50 µl PBS or PBS
containing AdNoxA1 or AdGFP vector (1×109 pfu) was injected through a catheter and
incubated for 30 min. After removal of this solution, the external carotid artery was ligated and
blood flow to the internal carotid artery was restored. The arteriotomy site was ligated by tying
the previously placed suture and skin incision was closed with 7–0 sutures (see supplemental
materials).
Human Carotid Arteries
Fresh frozen human carotid arteries, collected during autopsy performed 10–12 hours after
death, were obtained from National Disease Research Interchange (Philadelphia, PA). Carotid
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artery endarterectomy samples were collected at St Thomas’ Hospital, London under informed
consent. The use of human specimens was approved by UNC IRB. Carotid atherosclerotic
lesions were graded as normal ― no lesions, Type I ― very initial lesions, II ― first grossly
visible lesions characterized by foam cells and lipid droplets in intimal SMC and droplets of
extracellular lipid and III ― intermediate lesions according to AHA Atherosclerotic Plaque
Classification.27
Histology and Morphometry
Carotid artery sections were stained with combined Masson’s trichrome elastic stain or oil red
O and morphometric analysis was performed (see supplemental materials).
Immunohistochemistry
NoxA1 staining of carotid artery and aortic sections was described online in the supplemental
materials.
Statistical Analysis
Data are presented as mean ± SEM. All data were analyzed using one-way ANOVA followed
by Newman-Keuls multiple comparison test. Differences were considered significant at
P<0.05.
Results
Confirmation of NoxA1 Expression in Mouse Aortic VSMC
The molecular composition of vascular wall NADPH oxidases continues to be investigated
because of its complexity. Multiple possible subunit combinations, variability between cell
types, in the same cell type from different species and even in a single cell type (VSMC) from
different anatomic locations have all been demonstrated.28 An important remaining question
is whether one or both activating subunits, p67phox or NoxA1, are functionally important. We
began by investigating expression levels and previously reported that p67phox was not
detectable in human and rat aortic VSMC.15 Ambasta et al.20 recently reported the expression
of NoxA1, a p67phox homologue, in mouse aortic VSMC by Western analysis. To determine
whether NoxA1 is expressed in mouse VSMC, we performed RT-PCR amplifying a region
from 247–1169 bp of NoxA1 coding sequence. We were able to amplify the expected (923 bp)
fragment using NoxA1 cDNA, but not cellular RNA as the template, indicating that the PCR
product was not amplified from the contaminating genomic DNA present in the RNA
preparation (Figure 1A). Sequence analysis of the PCR product confirmed the NoxA1
expression in mouse aortic VSMC. As with human and rat aortic VSMC, p67phox protein was
not expressed in mouse aortic VSMC as well (data not shown). These data indicate that NoxA1
is the p67phox homologue expressed in mouse aortic VSMC.
NoxA1 Interacts with p47phox
It was previously demonstrated that fluorescent fusion proteins of NoxA1 and p47phox, when
expressed in mouse VSMC, are translocated from cytosol to the membrane and cytoskeleton
after stimulation with epidermal growth factor.20 This is consistent with the hypothesis that
p47phox binds NoxA1 and forms a functional NADPH oxidase at the membrane in an
analogous manner to association of the complex in phagocytes. We used immunoprecipitation/
Western analysis to address the interaction of NoxA1 with p47phox and determine if
physiologic factors that modulate ROS production, such as thrombin, also effect the NoxA1-
p47phox interaction. Because NoxA1 specific antibodies were not available at this time, we
infected p47phox- deficient mouse VSMC with adenoviruses encoding myc-tagged p47phox
and HA-tagged NoxA1 (Figure 1B). Cells were treated with or without thrombin for 10 minutes
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and immunoprecipitation was performed with anti-HA antibody. Western blot analysis with
anti-myc antibody showed a significant increase in the interaction of NoxA1 with p47phox
after thrombin stimulation (Figure 1C). These results confirm that interaction of NoxA1 with
p47phox is an essential initial event in the assembly of a functional NADPH oxidase upon
agonist stimulation in mouse VSMC.
NoxA1 is Essential for Thrombin-induced ROS Production in Mouse VSMC
To determine whether NoxA1 is required for ROS production, wild-type mouse aortic VSMC
were infected with retroviruses encoding either NoxA1-specific shRNA or scrambled shRNA
(Figure 2A). NoxA1-specific shRNA infection resulted in approx. 90% decrease in the
expression of a 51-kDa band recognized by the NoxA1 antibodies confirming the effectiveness
of shRNA in regulating NoxA1 expression. In addition, regulation of NoxA1 expression using
retroviral NoxA1 shRNA or adenoviral NoxA1 constructs had no effect on Nox1 expression
as measured by real-time RT-PCR (Supplemental Figure IA). The manipulation of NoxA1
expression by these methods did not cause cellular toxicity (data not shown) or activation of
cellular stress response as measured by HSP70 levels (Supplemental Figure IB). In cells not
infected with NoxA1 shRNA, treatment with thrombin for 10 minutes significantly increased
(P<0.001) ROS production as measured by the oxidation of H2DCF-DA (Figure 2B) and by
L012 chemiluminescence (Figure 2C). Thrombin-induced ROS generation was largely
inhibited by pretreatment with diphenyleneiodonium (DPI), a flavoprotein inhibitor.
Suppression of NoxA1 by infection of VSMC with retrovirus encoding NoxA1 shRNA had
no significant effect on basal ROS production. However, thrombin-induced ROS generation
in mouse VSMC expressing NoxA1 shRNA was significantly (P<0.01), but not completely
inhibited. Infection of VSMC with retrovirus encoding scrambled shRNA had no effect on
thrombin-induced ROS generation (Figures 2B & 2C). Consistent with these observations,
conversion of DHE to ethidium, a sensitive marker for O2.− generation, was markedly
attenuated in thrombin-treated VSMC expressing NoxA1 shRNA, but not scrambled shRNA
(Figure 2D). Together, these data indicate that NoxA1 is necessary for agonist-induced
increases in ROS production in mouse VSMC. Further, these data are consistent with the notion
that either low levels of NoxA1 (or an undetectable level of p67phox) are sufficient for basal
ROS production.
Overexpression of NoxA1 Increases ROS Production in Wild-type, But Not in p47phox−/− and
Nox1−/− VSMC
It has been reported that in endothelial dysfunction and atherosclerosis increased ROS
production is associated with enhanced expression of NoxA1 homologue, p67phox.29,30
Similarly, increased p67phox and other NADPH oxidase subunit gene expression was observed
in vascular cells in response to pathophysiological agonists31 and is correlated with increased
ROS production.32 To determine the effect of increased expression of NoxA1 on thrombin-
induced ROS generation, wild-type and p47phox knockout mouse aortic VSMC infected with
control adenovirus or adenovirus expressing HA-tagged NoxA1 were quiesced for 72 hours
and then left untreated or treated with thrombin for 10 minutes. Infection with HA-tagged
NoxA1 adenovirus caused a marked increase in the expression of NoxA1 in both wild-type
and p47phox knockout VSMC (Figure 3A). As previously reported,25 thrombin significantly
increased ROS production in wild-type (P<0.05) but not in p47phox−/− (Figure 3B) and
Nox1−/− (Figure 3C) VSMC . NoxA1 overexpression potentiated thrombin-induced ROS
generation in wild-type VSMC (P<0.001) but had no effect on ROS generation in
p47phox−/− (Figure 3B) and Nox1−/− (Figure 3C) cells. These data confirm that interaction of
p47phox with NoxA1 is necessary for agonist-induced ROS generation and suggest that
modulation of NoxA1 under pathophysiological conditions would increase oxidative stress in
the vasculature.
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Downregulation of NoxA1 Expression Decreases Thrombin-induced Proliferation of VSMC
We have previously shown that thrombin promotes VSMC proliferation in a ROS-dependent
manner through the activation of NADPH oxidase.9,15 So we next examined the role of NoxA1
in thrombin-induced VSMC proliferation (Figure 3D). Growth-arrested mouse aortic VSMC,
infected with retroviruses encoding either NoxA1-specific shRNA or scrambled shRNA, were
treated with or without thrombin in presence and absence of DPI. Thrombin induced a 2.8-fold
increase in DNA synthesis in VSMC expressing scrambled shRNA, as measured by thymidine
uptake, an effect that was significantly inhibited by DPI (P < 0.001). Thrombin-induced DNA
synthesis increased only 1.8-fold in VSMC expressing NoxA1 shRNA compared to the
respective control, but was significantly less than that in cells infected with scrambled shRNA
(P<0.001). Importantly, DPI pretreatment reduced thrombin-induced increases in DNA
synthesis in cells expressing NoxA1 shRNA. This suggests that the residual increase in ROS
levels in these cells contributes to increased thymidine uptake. DPI had no effect on basal
thymidine uptake in VSMC expressing either NoxA1 shRNA or scrambled shRNA. Together
these data indicate that NoxA1 contributes to agonist-induced proliferative response of VSMC.
Suppression of NoxA1 Expression Decreases Thrombin-induced Activation of Protein
Kinases in Mouse Aortic VSMC
ROS derived from vascular NADPH oxidases serve as second messengers to activate multiple
intracellular proteins that play an important role in the physiology and pathophysiology of
vascular cells.33 To determine the role of NoxA1-containing NADPH oxidases in thrombin-
induced VSMC proliferation, we examined the activation of redox-sensitive protein kinases
such as Janus kinase 2 (JAK2), Akt/protein kinase B and p38 mitogen-activated protein kinase
(p38 MAP kinase) in NoxA1 shRNA and scrambled shRNA expressing wild-type VSMC
treated with thrombin (Figure 4). Western blot analysis of thrombin-stimulated VSMC lysates
with a phospho-specific JAK2 antibody showed a significant increase in JAK2 tyrosine
phosphorylation at 10 minutes in scrambled shRNA expressing cells (2.20 ± 0.55 fold increase,
P<0.001), which was abrogated by pretreatment with DPI (P<0.001) (Figure 4A). In contrast,
no such increase in JAK2 phosphorylation in response to thrombin treatment was observed in
VSMC expressing NoxA1 shRNA. Thrombin treatment significantly stimulated Akt/PKB
phosphorylation at 10 minutes in both scrambled shRNA (3.70 ± 0.30 fold increase, P<0.001)
and NoxA1 shRNA expressing VSMC (1.57 ± 0.21 fold increase, P<0.01) (Figure 4B).
However, Akt/PKB phosphorylation in NoxA1 shRNA expressing cells was significantly less
than that in scrambled shRNA expressing cells (P<0.001) and was completely abrogated by
pretreatment with DPI in both the cells.
Phosphorylation of p38 MAPK increased significantly in scrambled shRNA (2.33 ± 0.20 fold
increase, P<0.001) and in NoxA1 shRNA expressing VSMC (1.27 ± 0.11 fold increase,
P<0.01) treated with thrombin (Figure 4C). Similar to its effect on Akt/PKB phosphorylation,
p38 MAP kinase phosphorylation was significantly decreased in NoxA1 shRNA expressing
VSMC compared with scrambled shRNA expressing VSMC (P<0.001). Thrombin-induced
p38 MAP kinase activation in scrambled shRNA expressing VSMC was abrogated by DPI
pretreatment. These data indicate that NoxA1-containing NADPH oxidase contributes to
VSMC proliferation by the activation of mitogenic intracellular signaling pathways.
TNFα, Not Thrombin, Increased the Expression of NoxA1, and NoxA1 shRNA Inhibited
TNFα-induced ROS Production in VSMC
We next examined the effect of thrombin on NoxA1 expression by RT-PCR. Although NoxA1
is essential for thrombin-induced ROS generation, thrombin (1 U/mL) per se did not induce
NoxA1 expression in mouse VSMC (data not shown). However, treatment with tumor necrosis
factor-α (TNFα, 20 ng/mL) for 4 hours significantly increased NoxA1 expression (4.35 ± 1.70
fold increase, P<0.05) in mouse VSMC (Figure 5A). Angiotensin II (100 nmol/L) was a weak
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inducer of NoxA1 expression (1.92 ± 0.68 fold increase at 4 hours treatment) (Figure 5A). In
contrast to the report of Honjo et al.34 in human umbilical vein endothelial cell line, oxidized
low-density lipoprotein (30 µg/mL or 60 µg/mL) had no stimulatory effect on NoxA1
expression in mouse VSMC for up to 24 hours of treatment (data not shown).
Consistent with real-time RT-PCR data, we observed a significant increase in NoxA1 protein
expression in VSMC treated with TNFα for 8 hours (P<0.05) (Figure 5B and 5C). As in the
case of thrombin, NoxA1 shRNA expression significantly attenuated TNFα-induced ROS
generation in mouse VSMC (Figure 5D). These data indicate that thrombin regulates ROS
generation without affecting NoxA1 expression levels, whereas other agonists might enhance
ROS production by modulating NoxA1 expression.
NoxA1 Overexpression Increases Superoxide Production in Injured Carotid Arteries and
Enhances Neointimal Hyperplasia
We also examined whether NoxA1-dependent increased production of ROS in VSMC
observed in vitro occurs in arterial VSMC in vivo and NoxA1-dependent activation of NADPH
oxidase results in enhanced neointimal hyperplasia. Mouse carotid arteries were subjected to
guidewire injury and then infected with a recombinant adenovirus encoding NoxA1 and GFP,
a control, empty adenovirus expressing only GFP or only treated with PBS. Three days after
adenovirus infection, histochemical analysis revealed NoxA1 overexpression in AdNoxA1-
infected vessels (Supplemental Figure IIA). DHE staining of injured carotid arteries showed
a significant increase (P<0.001) in O2.− levels in the medial VSMC (Supplemental Figure IIB
and Figure 6A). Fifteen days after guidewire injury and adenovirus infection, neointimal
hyperplasia was assessed morphologically and by morphometric analysis (Figure 6B and
Supplemental Figure IIC). Compared with empty adenovirus-infected mice, adenovirus
NoxA1 expressing mice had significantly increased (P<0.05) neointimal hyperplasia. Further,
immunoreactive NoxA1 expression in neointima 15 days after injury was confined to smooth
muscle α-actin positive cells (Figure 6C). Neointimal hyperplasia is correlated with increased
intimal SMC proliferation as shown by enhanced immunostaining with proliferating cell
nuclear antigen antibody (Figure 6D). We have also observed that NoxA1 overexpression in
VSMC results in increased migration as determined by the in vitro scratch assay (Supplemental
Figure III). Intriguingly, injury per se had no effect on NoxA1 levels in the carotid artery.
However, NoxA1 expression is increased in aortas and atherosclerotic lesions from ApoE−/−
mice (Figure 7). Together, these data suggest that in mouse carotid artery injury model,
localized overexpression of NoxA1 stimulates O2.− production resulting in increased medial
VSMC migration and proliferation and enhanced neointima formation.
NoxA1 is Expressed in Early Atherosclerotic Lesions of Human Carotid Arteries
To determine the clinical relevance of our NoxA1 data from cell culture experiments and mouse
atherosclerosis models, we investigated NoxA1 expression in normal, early and relatively
advanced (intermediate) atherosclerotic lesions in human carotid arteries (Figure 8). We
analyzed a total of 29 samples of which 22 were male and 7 female. The subjects ranged in
age from 21–89 years. NoxA1 expression, which was weak in normal carotid arteries, increased
significantly in the intimal and medial SMC of early (Type I and II) atherosclerotic lesions.
Expression of p67phox was confined to endothelial layer in both normal and early
atherosclerotic arteries. However, the expression of both NoxA1 and p67phox increased
significantly in the intimal and medial SMC of early advanced (Type III) atherosclerotic
lesions. The presence of NoxA1 and p67phox in VSMC was confirmed by staining with α-
actin (Figure 8). Though our small sample size precludes a definitive statement, NoxA1 and
p67phox expression in carotid atherosclerotic lesions does not seem influenced by the gender
of the subjects. These data suggest that NoxA1 plays a role in the development of human
atherosclerosis as well.
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An understanding of the precise molecular composition of vascular NADPH oxidases is
essential to elucidate the contribution of cell-specific oxidases in vascular pathology. In this
study we confirmed that NoxA1 is a critical component of VSMC NADPH oxidase.20
Downregulation of NoxA1 expression inhibited thrombin-induced O2.− production, mitogenic
protein activation and proliferation of VSMC whereas its upregulation increased thrombin-
induced O2.− production. Localized overexpression by adenovirus-mediated delivery of
NoxA1 enhanced neointimal hyperplasia in the mouse carotid artery injury model indicating
that regulation of NoxA1 expression could modulate VSMC NADPH oxidase activity under
pathophysiologic conditions.
It is known that rodent VSMC NADPH oxidase has unique composition—presence of Nox1
and Nox4 and the absence of Nox2 isoform— compared to other vascular cells.4,35–37
However, Nox1-containing VSMC NADPH oxidase is similar to other vascular cell and
leukocyte NADPH oxidases in that its activity is dependent on other subunits of the enzyme,
p22phox, p47phox and Rac.9,11,12,38 Recently Ambasta et al.20 have demonstrated that NoxA1
is the p67phox homologue in functional mouse VSMC NADPH oxidase. In the present study,
we confirmed this observation by RT-PCR amplification and sequencing of NoxA1 from
mouse VSMC. Our observation that thrombin activates the interaction of p47phox with NoxA1
is consistent with the data of agonist-induced membrane cotranslocation of NoxA1 and
p47phox fusion proteins in VSMC.20 Further support for p47phox and NoxA1 interaction in
activating VSMC NADPH oxidase is obtained from the data in the current study that NoxA1
overexpression enhances thrombin-induced ROS production in wild-type but not in
p47phox−/− VSMC. Activated p47phox binds with NoxA1 and interacts with Nox1 at the
membrane to increase O2.− production upon agonist treatment. This is corroborated by the
coimmunoprecipitation of NoxA1 with Nox1 in HEK293 cells transfected with Nox1, NoxO1
and NoxA1 fusion proteins.20 Additionally, the critical role of NoxA1 in O2.− production is
evident from negligible ROS generation in cells overexpressing Nox1 and NoxO1 in the
absence of NoxA1.
NoxA1 plays a critical role in modulating the phenotype of VSMC because depletion of this
protein using retroviral shRNA not only inhibits thrombin-induced ROS generation but also
significantly attenuates thrombin-stimulated cell proliferation. Our data also indicate that
NoxA1 functions in tandem with phosphorylated p47phox in agonist-induced stimulation of
Nox1-containing NADPH oxidase because increased ROS generation was observed in NoxA1
overexpressing VSMC treated with thrombin and NoxA1 overexpression per se had no effect
on ROS generation.
NoxA1 is not expressed in high abundance in mouse VSMC20 and we did not observe any
significant increase in its expression following thrombin treatment. However, a robust increase
in NoxA1 expression and NoxA1-dependent NADPH oxidase activation observed in response
to TNFα suggests that both the presence of NoxA1 and its expression levels play a regulatory
role in VSMC NADPH oxidase activation. In this context, it is worth noting that angiotensin
II-induced transcriptional regulation of p67phox enhances NADPH oxidase activity in aortic
endothelial cells39 and adventitial fibroblasts.40 Interestingly, p67phox has also been proposed
as a putative rate-limiting co-factor in NADPH oxidase activation.41,42
We previously showed that decreased levels of activated mitogenic proteins and attenuated
cell proliferation occur downstream of impaired agonist-induced ROS production in
p47phox−/− VSMC.9,43 Our current data that depletion of NoxA1 in VSMC significantly
decreases thrombin-induced JAK2, Akt and p38 MAPK phosphorylation supports the
hypothesis that agonist-induced NADPH oxidase activation plays an important role in VSMC
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proliferation. These data are also consistent with redox-sensitive regulation of JAK2, Akt and
p38 MAP kinase in VSMC.4,13,26,44.
Increased medial O2.− production and enhanced neointimal hyperplasia observed in the present
investigation in AdNoxA1-infected injured carotid arteries is consistent with the notion that
vascular NADPH oxidase plays a potentially critical role in vascular disease.4,9,43 Further,
consistent with the observation of Ambasta et al.20 NoxA1 expression was abundant in
proliferating VSMC in injured carotid arteries. The fact that NoxA1 expression is not
upregulated by injury per se, but seems to increase in atherosclerotic lesions suggests that
NoxA1 expression is fine-tuned to different pathophysiologic stimuli. In this context, it is worth
mentioning a recent report by Kim et al45 elucidating a novel mechanism for NoxA1-regulated
Nox1 activation in colon cell lines. Protein kinase A-dependent phosphorylation of NoxA1 at
Ser172 and Ser461 results in its interaction with 14–3–3ζ and consequent inhibition of Nox1
activity. It would be interesting to see whether a similar mechanism regulates NoxA1-
dependent Nox1 activity in vascular cells.
Interestingly, immunoreactive NoxA1 was present in the intimal and medial SMC of early
atherosclerotic lesions (Type I and II) whereas NoxA1 as well as p67phox were present in the
intimal and medial SMC of early advanced (Type III) atherosclerotic lesions of human carotid
arteries. In this context it is noteworthy that Clempus et al. have correlated modulation of rat
VSMC phenotypes with relative expression levels of Nox1 and Nox4.35 It would be interesting
to see whether a similar phenomenon occurs with regards to NoxA1- and p67phox-dependent
NADPH oxidase activity on cellular phenotype in human aortic VSMC.
In conclusion, our results demonstrate that NoxA1 expression regulates NADPH oxidase
activity in mouse VSMC. Furthermore, expression of NoxA1 regulates thrombin-induced
activation of redox-sensitive mitogenic protein kinases. Increased neointimal hyperplasia in
injured mouse carotid arteries following localized overexpression of NoxA1 and the presence
of NoxA1 in mouse and human atherosclerotic lesions suggest that NoxA1 is a potential target
for therapeutic intervention. We believe that these findings support further investigation of
NoxA1 expression in vascular diseases.
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NoxA1 is expressed and interacts with p47phox in mouse aortic VSMC. A, The cDNA
generated from VSMC was used as a template for PCR with NoxA1-specific primers to amplify
a 923-bp NoxA1 coding sequence. pcDNA3-NoxA1 was used as a positive control and total
RNA as a negative control. B, p47phox−/− VSMC were infected with adenoviruses encoding
either HA-NoxA1 or Myc-p47phox and Western blot analysis was performed with anti-Myc
or anti-HA antibodies. C, p47phox−/− VSMC infected with adenoviruses encoding HA-NoxA1
and Myc-p47phox were quiesced for 72 hours and then treated without or with thrombin (1 U/
mL) for 10 minutes. Cell lysates were immunoprecipitated (IP) with either anti-HA antibody
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or non-immune Rabbit IgG and Western blot (WB) analysis was preformed with anti-Myc or
anti-HA antibody.
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Suppression of NoxA1 expression decreases thrombin-induced ROS production. A, Wild-type
mouse aortic VSMC were infected with retroviruses encoding either scrambled shRNA or
NoxA1 shRNA. NoxA1 protein levels were determined by Western blot analysis using anti-
NoxA1 antibody. β-tubulin levels were used as loading controls. B, VSMC expressing
scrambled or NoxA1 shRNA were treated without or with thrombin (1 U/mL) after
pretreatment with DPI. ROS levels were determined by measuring DCF fluorescence (mean
± SEM, n=4; *P<0.001 vs respective controls; **P<0.01 vs thrombin-treated scrambled
shRNA expressing cells). C, ROS levels in the above mentioned VSMC were determined by
measuring L012 chemiluminescence (mean ± SEM, n=4; *P<0.001 vs respective controls;
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**P<0.01 vs thrombin-treated scrambled shRNA expressing cells). D, VSMC expressing
scrambled or NoxA1 shRNA were treated with or without thrombin and ROS production was
detected by DHE staining.
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NoxA1 expression levels affect thrombin-induced ROS generation and VSMC proliferation.
A, Wild-type and p47phox−/− VSMC were infected with either HA-NoxA1-encoding
adenovirus or empty adenovirus and Western analysis was performed with either anti-HA or
anti-β-actin antibodies. B, Wild-type and p47phox−/− VSMC, infected with either HA-NoxA1-
encoding adenovirus or empty adenovirus, were quiesced and then treated with thrombin (1
U/mL) for 10 minutes. ROS levels were determined by measuring DCF fluorescence (mean ±
SEM, n=4; *P<0.05 vs control; **P<0.001 vs thrombin-treated, empty adenovirus infected
cells). C, Wild-type and Nox1−/− VSMC, infected with either HA-NoxA1-encoding adenovirus
or empty adenovirus, were quiesced and then treated with thrombin (1 U/mL) for 10 minutes.
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ROS levels were determined by measuring L012 chemiluminescence (mean ± SEM, n=4;
*P<0.05 vs control; **P<0.05 vs thrombin-treated, empty adenovirus infected cells). D, Wild-
type mouse aortic VSMC infected with retroviruses encoding either scrambled shRNA or
NoxA1 shRNA were quiesced, pretreated with DPI for 1 hour prior to treatment with or without
thrombin (1 U/mL) for 16 hours. Cells were incubated with [3H]-thymidine for the last 3 hours.
Data presented are mean ± SEM (n=3) of three separate experiments (*P<0.001 vs respective
control; **P<0.001 vs thrombin-treated scrambled shRNA expressing cells; #P<0.001 vs
respective control; ##P<0.001 vs thrombin-treated NoxA1 shRNA expressing cells;
***P<0.001 vs thrombin-treated, scrambled shRNA expressing cells).
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Depletion of NoxA1 expression attenuates redox-sensitive cellular signaling pathways.
Retrovirus-infected VSMC were quiesced, pretreated with DPI for 1 hour prior to treatment
without or with thrombin (1 U/mL) for 10 min. A, Representative Western blots of cell lysates
using anti-phosphotyrosine-specific JAK2 and anti-β-tubulin antibodies (left panel).
Densitometry analysis of JAK2 tyrosine phosphorylation (mean ± SEM, n=3; right panel).
*P<0.001 vs respective control; **P<0.001 vs thrombin-treated scrambled shRNA expressing
cells. B, Representative Western blots using anti-phosphospecific-Akt/PKB and anti-Akt/PKB
antibodies (left panel). Densitometric analysis of Akt phosphorylation (mean ± SEM, n=3;
right panel). *P<0.001 vs respective control; **P<0.001 vs respective thrombin-treated
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cells; #P<0.01 vs respective control; ##P<0.001 vs thrombin-treated scrambled shRNA
expressing cells. C, Representative Western blots using anti-phosphospecific-p38 MAPK and
anti-p38 MAPK antibodies (left panel). Densitometric analysis of p38 MAP kinase
phosphorylation (mean ± SEM, n=3; right panel). *P<0.001 vs respective control; **P<0.001
vs respective thrombin-treated cells; #P<0.05 vs respective control; ##P<0.001 vs thrombin-
treated scrambled shRNA expressing cells.
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TNFα induces NoxA1 expression and TNFα-induced ROS production was inhibited in NoxA1
shRNA expressing mouse VSMC. A, Real-time RT-PCR analysis of NoxA1 expression in
VSMC treated with 20 ng/mL TNFα or 100 nmol/L angiotensin II. Data expressed as fold
change relative to untreated control (mean ± SEM, n=3; *P<0.05 vs untreated cells). B, Western
analysis of NoxA1 protein expression in lysates from VSMC treated with 20 ng/ mL TNFα.
C, Densitometric analysis of NoxA1 protein (mean ± SEM, n=4; *P<0.05 vs untreated cells).
D, ROS production, as measured by DCF fluorescence, in VSMC expressing scrambled or
NoxA1 shRNA and treated with 20 ng/mL TNFα (mean ± SEM, n=4; *P<0.001 vs TNFα-
treated scrambled shRNA expressing cells).
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Exogenous NoxA1 overexpression in carotid arteries increases superoxide production and
induces neointimal hyperplasia. Quantification of confocal images of DHE-stained fresh-
frozen sections of guidewire-injured carotid arteries (A) infected with AdGFP or AdNoxA1
(mean ± SEM, n=8, *p<0.001). Representative sections of carotid arteries, 15 days after sham
or guidewire injury and sham infection or infection with AdGFP or AdNoxA1, were stained
with combined Masson’s trichrome elastin stain (B) and for NoxA1 (C), or proliferating cell
nuclear antigen (D).
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Immunoreactive NoxA1 expression is enhanced in atherosclerotic lesions of apoE−/− mice.
Western blot analysis of mouse aortic lysates using anti-NoxA1 or β-actin antibody (A).
Representative sections of frozen mouse aortas stained for immunoreactive NoxA1 (B), with
oil red O (C) or non-immune rabbit IgG (D).
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NoxA1 vs p67phox expression in different atherosclerotic lesion types in human carotid
arteries. A, Representative cross sections of human carotid arteries stained for immunoreactive
NoxA1, p67phox, oil red O and smooth muscle α-actin. B, Expression of NoxA1 and p67phox
as determined by immunohistochemistry scoring where 1 is weak, 2 moderate, and 3 strong
staining. The numerical scoring was confirmed by a second independent observer, blinded to
the initial score. Data represent the mean ± SEM (*P<0.01 vs N, **P<0.001 vs respective N).
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